Patents by Inventor Keith E. Robison

Keith E. Robison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8211640
    Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: July 3, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
  • Publication number: 20110171205
    Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: January 25, 2011
    Publication date: July 14, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
  • Publication number: 20100273989
    Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostic methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
    Type: Application
    Filed: December 22, 2008
    Publication date: October 28, 2010
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
  • Publication number: 20100136010
    Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: October 21, 2008
    Publication date: June 3, 2010
    Inventors: Rosana Kappeller-Libermann, David White, Keith E. Robison, Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
  • Publication number: 20090264361
    Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.
    Type: Application
    Filed: December 18, 2008
    Publication date: October 22, 2009
    Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
  • Publication number: 20090226450
    Abstract: The invention provides isolated nucleic acids molecules, designated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 15571, 2465, 14266, 2882, 52871, 8203 or 16852 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 15571, 2465, 14266, 2882, 52871, 8203 or 16852 gene has been introduced or disrupted. The invention still further provides isolated 15571, 2465, 14266, 2882, 52871, 8203 or 16852 proteins, fusion proteins, antigenic peptides and anti-15571, 2465, 14266, 2882, 52871, 8203 or 16852 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 23, 2009
    Publication date: September 10, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Martin R. Hodge, Clare M. Lloyd, Nadine S. Weich, Jose M. Lora, David White, Maria A. Glucksmann, Keith E. Robison, Inmaculada Silos-Santiago, Andrew D.J. Goodearl, Rory A.J. Curtis
  • Patent number: 7485431
    Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: February 3, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
  • Patent number: 7482171
    Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
    Type: Grant
    Filed: February 16, 2005
    Date of Patent: January 27, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
  • Patent number: 7258988
    Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: August 21, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
  • Patent number: 7083944
    Abstract: Novel CARD-12 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-12 proteins, the invention further provides CARD-12, fusion proteins, antigenic peptides and anti-CARD-12 antibodies. The invention also provides CARD-12 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-12 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 26, 2000
    Date of Patent: August 1, 2006
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: John Bertin, Keith E. Robison
  • Patent number: 6884771
    Abstract: The present invention relates to the discovery of novel genes encoding an angiotensin converting enzyme, Angiotensin Converting Enzyme-2 (ACE-2). The invention provides therapeutics, prognostic and diagnostics methods for treating blood pressure related disorders as well as various types of allergic conditions, among others. Also disclosed are screening assays for identifying compounds for treating and preventing these conditions.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: April 26, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Susan Acton, Keith E. Robison, Frank Y. Hsieh
  • Publication number: 20040006016
    Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 11, 2003
    Publication date: January 8, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, David White, Keith E. Robison, Kyle J. MacBeth, Joseph M. Carroll, William James Cook, Rachel E. Meyers, Miyoung Chun, Mark J. Williamson
  • Publication number: 20030219813
    Abstract: The invention relates to SCUBE molecules and generally to gene expression in vascular endothelial cells. The invention specifically relates to the discovery of a novel gene family containing the genes and proteins referred to herein as SCUBE1, SCUBE2 and SCUBE3 which can be expressed in endothelial cells. SCUBE proteins may be involved in the development of cardiovascular disease, hemostasis, thrombosis, inflammatory disease, bone metabolism disorders, urinary bladder disorders and breast disorders.
    Type: Application
    Filed: April 3, 2003
    Publication date: November 27, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ruey-Bing Yang, Chi Kin Domingos Ng, James E. Tomlinson, Laszlo G. Komuves, James N. Topper, Keith E. Robison
  • Publication number: 20030104505
    Abstract: The invention provides isolated nucleic acids molecules, designated Kinase and Phosphatase nucleic acid molecules, which encode novel protein kinase and protein phosphatase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Kinase and Phosphatase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Kinase and Phosphatase gene has been introduced or disrupted. The invention still further provides isolated Kinase and Phosphatase proteins, fusion proteins, antigenic peptides and anti-Kinase and Phosphatase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: April 12, 2002
    Publication date: June 5, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Keith E. Robison
  • Patent number: 6500628
    Abstract: The invention provides isolated nucleic acids molecules, designated Kinase and Phosphatase nucleic acid molecules, which encode novel protein kinase and protein Phosphatase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Kinase and Phosphatase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Kinase and Phosphatase gene has been introduced or disrupted. The invention still further provides isolated Kinase and Phosphatase proteins, fusion proteins, antigenic peptides and anti-Kinase and Phosphatase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: December 31, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Keith E. Robison
  • Publication number: 20020172981
    Abstract: The invention provides isolated nucleic acids molecules, designated Kinase and Phosphatase nucleic acid molecules, which encode novel protein kinase and protein phosphatase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Kinase and Phosphatase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Kinase and Phosphatase gene has been introduced or disrupted. The invention still further provides isolated Kinase and Phosphatase proteins, fusion proteins, antigenic peptides and anti-Kinase and Phosphatase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: September 7, 2001
    Publication date: November 21, 2002
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Keith E. Robison
  • Patent number: 6465232
    Abstract: The invention provides isolated nucleic acids molecules, designated Kinase and Phosphatase nucleic acid molecules, which encode novel protein kinase and protein phosphatase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Kinase and Phosphatase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Kinase and Phosphatase gene has been introduced or disrupted. The invention still further provides isolated Kinase and Phosphatase proteins, fusion proteins, antigenic peptides and anti-Kinase and Phosphatase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: October 15, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Keith E. Robison
  • Patent number: 6395889
    Abstract: The invention relates to polynucleotides encoding newly identified protease homologs. The invention also relates to the proteases. The invention further relates to methods using the protease polypeptides and polynucleotides as a target for diagnosis and treatment in protease-mediated disorders. The invention further relates to drug-screening methods using the protease polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the protease polypeptides and polynucleotides. The invention further relates to procedures for producing the protease polypeptides and polynucleotides.
    Type: Grant
    Filed: September 9, 1999
    Date of Patent: May 28, 2002
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Keith E. Robison
  • Patent number: 6331427
    Abstract: The invention relates to polynucleotides encoding newly identified protease homologs belonging to the superfamily of G-protein-coupled proteases. The invention also relates to the proteases. The invention further relates to methods using the protease polypeptides and polynucleotides as a target for diagnosis and treatment in protease-mediated disorders. The invention further relates to drug-screening methods using the protease polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the protease polypeptides and polynucleotides. The invention further relates to procedures for producing the protease polypeptides and polynucleotides.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: December 18, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Keith E. Robison
  • Patent number: 6309849
    Abstract: The invention provides isolated nucleic acids molecules, designated Kinase and Phosphatase nucleic acid molecules, which encode novel protein kinase and protein phosphatase polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Kinase and Phosphatase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Kinase and Phosphatase gene has been introduced or disrupted. The invention still further provides isolated Kinase and Phosphatase proteins, fusion proteins, antigenic peptides and anti-Kinase and Phosphatase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: October 30, 2001
    Assignee: Millennium Pharamaceuticals, Inc.
    Inventor: Keith E. Robison